Polen Capital, an investment management company, released its fourth-quarter investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here. The Polen 5Perspectives Small Growth Composite Portfolio returned -1.3% gross and -1.5% net of fees in the fourth quarter of 2025, compared to a 1.2% return of the Russell 2000 Growth Index. Following double-digit returns in 2Q and 3Q, small caps concluded the year with a 1.2% return in 4Q. Biotech stood out as a major performer during the quarter, expanding beyond the AI theme. The small-cap asset class has gained attention due to declining interest rates and improving earnings growth, but the firm is most excited about its structural tailwinds, including the rapid pace of innovation and the opportunity it presents for disciplined investors. Over the fourth quarter, the Strategy nearly doubled its Biotech exposure due to opportunities presented by rising interest rates, M&A, and AI tailwinds. The name of the Strategy changed from Polen U.S. Small Cap Growth to Polen 5Perspectives Small Growth, to emphasize the significance of the 5 viewpoints framework and the influence of perspective in investing. In addition, please check the Strategy’s top five holdings to know its best picks in 2025.
In its fourth-quarter 2025 investor letter, Polen 5Perspectives Small Growth Strategy highlighted Corcept Therapeutics Incorporated (NASDAQ:CORT). Corcept Therapeutics Incorporated (NASDAQ:CORT) is pharmaceutical company focuses on the development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders. On February 23, 2026, Corcept Therapeutics Incorporated (NASDAQ:CORT) stock closed at $35.34 per share. One-month return of Corcept Therapeutics Incorporated (NASDAQ:CORT) was -22.56%, and its shares lost 42.82% over the past 52 weeks. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $3.724 billion.
Polen 5Perspectives Small Growth Strategy stated the following regarding Corcept Therapeutics Incorporated (NASDAQ:CORT) in its fourth quarter 2025 investor letter:
“Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company focused on developing drugs that modulate cortisol activity, with its flagship product Korlym approved for Cushing’s syndrome and a growing pipeline in oncology and metabolic disorders. We feel Corcept is at an inflection point as it expands beyond its core indication, driven by promising Phase 3 data for relacorilant in adrenal cancer and other indications. However, during the quarter, the stock was pressured due to concerns about slower Korlym sales growth and uncertainty around timing of pipeline approvals.”
Corcept Therapeutics Incorporated (NASDAQ:CORT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 39 hedge fund portfolios held Corcept Therapeutics Incorporated (NASDAQ:CORT) at the end of the fourth quarter, up from 28 in the previous quarter. While we acknowledge the risk and potential of Corcept Therapeutics Incorporated (NASDAQ:CORT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Corcept Therapeutics Incorporated (NASDAQ:CORT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Corcept Therapeutics Incorporated (NASDAQ:CORT) and shared a list of biotechnology stocks with more than 50% upside. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
